Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 1 335.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (8.0%)
  • Dividend yield for the last twelve months 3.2%
  • Free cash flow yield -2.3% (LTM)
  • Share price is 33.4% higher than minimum and 26.3% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-73.8x vs
    )

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-1.5%)98.05
year average price 118.61  


year start price 107.70 2023-12-23

max close price 132.96 2024-06-24

min close price 96.31 2024-11-15

current price 98.05 2024-12-21
Common stocks: 2 528 810 012

Dividend Yield:  3.2%
FCF Yield LTM: -2.3%
EV / LTM EBITDA: -73.8x
EV / EBITDA annualized: 9.4x
Last revenue growth (y/y):  +8.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +9.1%
Historical growth of EBITDA:  +6.9%
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 247 950
Net Debt ($m): 26 140
EV (Enterprise Value): 274 090
EBITDA LTM ($m): -3 715
EV / LTM EBITDA: -73.8x
Price to Book: 5.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-12-20zacks.com

MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

2024-12-20zacks.com

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

2024-12-20fool.com

Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks

2024-12-19seekingalpha.com

Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time

2024-12-19businesswire.com

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

2024-12-18invezz.com

Merck's weight-loss pill deal: what it means for Eli Lilly

2024-12-18proactiveinvestors.com

Merck pens $2bn deal for obesity drug from China's Hansoh

2024-12-18zacks.com

Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

2024-12-18zacks.com

Merck to End Development of Two Cancer Candidates: Time to Sell?

2024-12-17zacks.com

Merck Ends Development of Two Experimental Cancer Drugs
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data